Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of Nalmefene Implants in Healthy Subjects
NCT07325279Phase 1Recruiting
- Sponsor
- ReacX Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nalmefene in opioid use disorder (OUD) (2 cohorts), sponsored by ReacX Pharmaceuticals. Primary endpoints: Number of participants with Adverse Events, Columbia-Suicide Severity Rating Scale at Day 2 and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
nalmefene
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07325279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325279.